Novartis Ag

Beth Israel Deaconess Medical Center, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Tony Fleming

Lu Huang

Aida Abujoub

Connie Hong

John Blankenship

Brian Holmberg

Chonghui Zhang

Dexiu Bu

Jean-Pierre Kinet

Haihui Lu

Jennifer Brogdon

Saurabh Saha

Matthew T Burger

Glenn Dranoff

Brad St Croix

Xiaoyan Michelle Zhang

Boris Engels

Christian Kunz

Brian Walter Granda

Carla Guimaraes

Vivek Rauniyar

Markus Waldhuber

Michael R Greene

Xu Zhu

Joseph Anthony D'Alessio

Elizabeth Dorothy Pratico

Hyungwook Lim

Serena De Vita

Anniesha Hack

Joni Waiee Lam

Andrew Price

Louise Treanor

Olja Kodrasi

Attilio Bondanza

Akash Sohoni

Andrew Marc Stein

Eusebio Manchado Robles

Mary Beth Hilton

Rou-fun Kwong

Amit Chaudhary

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

Binding molecules against BCMA and uses thereof

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

BCMA chimeric antigen receptors and uses thereof

This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Antibodies to PMEL17 and conjugates thereof

Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.

TEM8 antibodies, conjugates thereof, and their use

Calcium independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the Fc&#x3b3;RIII and Fc&#x3b5;RI receptors, is described, as well as methods of inhibiting allergic processes.

Calcium-independent negative regulation by CD81 of receptor signalling

Calcium independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the Fc&ggr;RIII and FC&egr;RI receptors, is described, as well as methods of inhibiting allergic processes.

Calcium-independent negative regulation by CD81 of receptor signaling

Growing community of inventors

Stow, MA, United States of America

Tony Fleming